Dec 20, 2022 8:00 am EST Eyenovia Announces Participation at the 2023 International Consumer Electronics Show
Dec 13, 2022 8:00 am EST Eyenovia Announces FDA Acceptance of New Drug Application for MydCombi™ for In-Office Pupil Dilation
Dec 8, 2022 8:00 am EST Eyenovia Announces Promotion of Bren Kern to Chief Operating Officer and Corporate Vice President
Nov 29, 2022 8:00 am EST Eyenovia Announces $15 Million Credit Facility with Avenue Venture Debt Fund
Nov 10, 2022 4:05 pm EST Eyenovia Reports Third Quarter 2022 Financial Results and Provides Business Update
Oct 20, 2022 8:00 am EDT Eyenovia Announces Positive Results from VISION-2 Phase 3 Study of MicroLine as a Potential On-Demand Treatment for Presbyopia
Sep 30, 2022 8:00 am EDT Eyenovia Announces Planned Retirement of Lead Independent Director Ken Lee, Jr.